OpenURL Connection Search

Select item for more details and to access through your institution.

Gastrointestinal symptom severity in irritable bowel syndrome, inflammatory bowel disease and the general population.
Published in:
Neurogastroenterology & Motility, 2017, v. 29, n. 5, p. n/a, doi. 10.1111/nmo.13003
By:
- Lee, A. D.;
- Spiegel, B. M.;
- Hays, R. D.;
- Melmed, G. Y.;
- Bolus, R.;
- Khanna, D.;
- Khanna, P. P.;
- Chang, L.
Publication type:
Article
Consequences of frequent nocturnal gastro-oesophageal reflux disease among employed adults: symptom severity, quality of life and work productivity.
Published in:
Alimentary Pharmacology & Therapeutics, 2007, v. 25, n. 4, p. 487, doi. 10.1111/j.1365-2036.2006.03189.x
By:
- DUBOIS, R. W.;
- AGUILAR, D.;
- FASS, R.;
- ORR, W. C.;
- ELFANT, A. B.;
- DEAN, B. B.;
- HARPER, A. S.;
- YU, H.‐T.;
- MELMED, G. Y.;
- LYNN, R.;
- SINGH, A.;
- TEDESCHI, M.
Publication type:
Article
Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy.
Published in:
Alimentary Pharmacology & Therapeutics, 2004, v. 19, n. 2, p. 197, doi. 10.1111/j.0269-2813.2004.01834.x
By:
- Dubois, R. W.;
- Melmed, G. Y.;
- Henning, J. M.;
- Laine, L.
Publication type:
Article
Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study.
Published in:
Alimentary Pharmacology & Therapeutics, 2015, v. 42, n. 3, p. 330, doi. 10.1111/apt.13251
By:
- Sandborn, W. J.;
- Melmed, G. Y.;
- McGovern, D. P. B.;
- Loftus, E. V.;
- Choi, J. M.;
- Cho, J. H.;
- Abraham, B.;
- Gutierrez, A.;
- Lichtenstein, G.;
- Lee, S. D.;
- Randall, C. W.;
- Schwartz, D. A.;
- Regueiro, M.;
- Siegel, C. A.;
- Spearman, M.;
- Kosutic, G.;
- Pierre‐Louis, B.;
- Coarse, J.;
- Schreiber, S.
Publication type:
Article

Found: 4

Gastrointestinal symptom severity in irritable bowel syndrome, inflammatory bowel disease and the general population.

Consequences of frequent nocturnal gastro-oesophageal reflux disease among employed adults: symptom severity, quality of life and work productivity.

Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy.

Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study.